NRAS and chronic obstructive pulmonary disease: Navarixin has been successful in alleviating pulmonary inflammation in patients with chronic obstructive pulmonary disease (Rennard et al, 2015) and would be worth testing in patients at risk of lung metastasis from NRAS‐mutant tumors.